Document Detail


Suppression of acid secretion in peptic ulcer disease.
MedLine Citation:
PMID:  7673607     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Until recently, suppression of gastric acid secretion in patients with peptic ulcer was empirical and of unproven value. Anticholinergic drugs had only modest inhibitory effects on acid secretion, many side effects, and uncertain efficacy. Controlled trials using antacids demonstrated the value of reducing gastric acidity for healing duodenal ulcer. The discovery of histamine-2 (H2) receptor antagonists in the 1970s and the introduction of H+,K(+)-ATPase inhibitors in the 1980s made reduction of acid secretion the first-choice modality for healing and preventing recurrences of duodenal and gastric ulcers. The demonstration in the late 1980s and early 1990s that Helicobacter pylori (Hp) was a major risk factor for duodenal and gastric ulcer recurrences suggested that peptic ulcer could be cured by eradicating this organism from the stomach. However, antibiotic eradication of Hp can be difficult, often requiring simultaneous administration of a drug that suppresses acid secretion. Therefore, H2 and proton pump inhibitors continue to play a role in the management of duodenal and gastric ulcers associated with Hp and also play a primary role in the therapy of other acid-related disorders, such as gastroesophageal reflux diseases, stress ulcers, ulcers associated with nonsteroidal anti-inflammatory drugs, and gastrinoma (Zollinger-Ellison syndrome) and other acid hypersecretory states.
Authors:
M Feldman
Related Documents :
11237187 - Antidiabetogenic activity of oleanolic acid glycosides from medicinal foodstuffs.
15456457 - Review article: trials on reflux disease -- the role of acid secretion and inhibition.
12514027 - Compost-induced suppression of pythium damping-off is mediated by fatty-acid-metabolizi...
10751237 - Gastric acid suppression does not promote clostridial diarrhoea in the elderly.
10791577 - Modulation of lipogenic enzymes, fatty acid synthase and delta9-desaturase, in relation...
903047 - The mechanism of adipocere formation. ii. separation and identification of oxo fatty ac...
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Review    
Journal Detail:
Title:  Journal of clinical gastroenterology     Volume:  20 Suppl 1     ISSN:  0192-0790     ISO Abbreviation:  J. Clin. Gastroenterol.     Publication Date:  1995  
Date Detail:
Created Date:  1995-10-17     Completed Date:  1995-10-17     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7910017     Medline TA:  J Clin Gastroenterol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  S1-6     Citation Subset:  IM    
Affiliation:
Department of Internal Medicine, University of Texas, Southwestern Medical School at Dallas, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antacids / therapeutic use*
Gastric Acid / secretion*
Helicobacter Infections / drug therapy,  metabolism
Helicobacter pylori / drug effects
Histamine H2 Antagonists / therapeutic use*
Humans
Peptic Ulcer / drug therapy*,  metabolism,  microbiology
Chemical
Reg. No./Substance:
0/Antacids; 0/Histamine H2 Antagonists

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Sympatholytic effect of clonidine depends on the respiratory phase in rat splanchnic nerve.
Next Document:  Mucosal regeneration of gastric ulcer confirmed by electronic endoscopy.